CardioFocus Revenue and Competitors

Location

$224.8M

Total Funding

Estimated Revenue & Valuation

  • CardioFocus's estimated annual revenue is currently $20.6M per year.(i)
  • CardioFocus's estimated revenue per employee is $251,000
  • CardioFocus's total funding is $224.8M.

Employee Data

  • CardioFocus has 82 Employees.(i)
  • CardioFocus grew their employee count by -23% last year.

CardioFocus's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEO & PresidentReveal Email/Phone
3
VP Product DevlopmentReveal Email/Phone
4
VP Business DevelopmentReveal Email/Phone
5
VP SalesReveal Email/Phone
6
VP OperationsReveal Email/Phone
7
VP - Finance And AdministrationReveal Email/Phone
8
VP, Regulatory Affairs & Quality AssuranceReveal Email/Phone
9
ControllerReveal Email/Phone
10
VP, OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is CardioFocus?

CardioFocus is a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AFib), the most common heart arrhythmia. The company?s FDA-approved HeartLight Endoscopic Ablation System has successfully treated more than 6,000 patients in the United States, Europe and Japan. The HeartLight System is a revolutionary catheter ablation technology that along with direct visualization and titratable laser energy, represents a new standard for AFib ablation. CardioFocus is headquartered in Marlborough, MA. For more information, visit www.CardioFocus.com. Social Media Community Guidelines: https://bit.ly/2IDIBZR

keywords:Biotechnology

$224.8M

Total Funding

82

Number of Employees

$20.6M

Revenue (est)

-23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CardioFocus News

2022-04-17 - Atrial Fibrillation Market Size And Forecast | AtriCure Inc ...

... Biosense Webster Inc., St. Jude Medical Inc., Johnson & Johnson Ltd., CardioFocus Inc., Sanofi-Aventis, Endoscopic Technologies Inc.,...

2022-04-06 - Atrial Fibrillation Market is estimated to exhibit a CAGR of 13.4 ...

... Abbott Laboratories, AtriCure, Inc., Biosense Webster, Inc., Boston Scientific Corporation, CardioFocus, Inc., Johnson and Johnson Ltd.

2021-06-23 - CardioFocus Receives Regulatory Approval to Market HeartLight X3 System in Japan

MARLBOROUGH, Mass., June 23, 2021 /PRNewswire/ -- CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the Japanese Ministry of Health, Labor and Welfare ("MHLW") has approved the company's HeartLight X3 Syst ...

2021-06-02 - CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China

MARLBOROUGH, Mass., June 2, 2021 /PRNewswire/ -- CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced today that it has entered into a licensing and distribution agreement with China Grand Pharmaceutical (Grand Pharma) ...

2021-02-25 - CardioFocus Announces The Publication Of HeartLight X3 Pivotal Study Data

MARLBOROUGH, Mass., Feb. 25, 2021 /PRNewswire/ -- CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that results from its HeartLight® X3 Pivotal Study were published in the premier journal Circulation: Arrhythm ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.5M8222%N/A
#2
$14.8M820%N/A
#3
$20.8M820%N/A
#4
$26.9M8228%N/A
#5
$18.6M826%N/A